A Comparison of the Clinical and Radiological Extent of Denosumab (Xgeva) Related Osteonecrosis of the Jaw: A Retrospective Study.

Fiche publication

Date publication

mai 2021

Journal

Journal of clinical medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DOLIVET Gilles

Tous les auteurs :
Assili Z, Dolivet G, Salleron J, Griffaton-Tallandier C, Egloff-Juras C, Phulpin B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34071481

Résumé

Medication-related osteonecrosis of the jaw (MRONJ) is a severe side effect of antiresorptive medication. The aim of this study was to evaluate the incidence of denosumab-related osteonecrosis of the jaw and to compare the clinical and radiological extent of osteonecrosis. A retrospective study of patients who received Xgeva at the Institut de Cancérologie de Lorraine (ICL) was performed. Patients for whom clinical and radiological (CBCT) data were available were divided into two groups: "exposed" for patients with bone exposure and "fistula" when only a fistula through which the bone could be probed was observed. The difference between clinical and radiological extent was assessed. The -value was set at 0.05, and a total of 246 patients were included. The cumulative incidence of osteonecrosis was 0.9% at 6 months, 7% at 12 months, and 15% from 24 months. The clinical extent of MRONJ was significantly less than their radiological extent: in the "exposed" group, 17 areas (45%) were less extensive clinically than radiologically ( < 0.001) and respectively 6 (67%) for the "fistula" group ( < 0.031). It would seem that a CBCT is essential to know the real extent of MRONJ. Thus, it would seem interesting to systematically perform a CBCT during the diagnosis of MRONJ, exploring the entire affected dental arch.